Hutchmed shares slide as recalls cancer treatment Tazverik
9th Mar 2026 10:49
(Alliance News) - Hutchmed China Ltd on Monday saw its shares fall after reporting the withdrawal of a cancer medication which it licenses from Ipsen SA. Read More
| Price | 214.00p on 11-03-2026 at 11:25:13 |
|---|---|
| Change | 0.00p 0% |
| Buy | 212.00p |
| Sell | 201.00p |
| Last Trade: | Buy 235.00 at 209.80p |
| Day's Volume: | 1,074 |
| Last Close: | 214.00p |
| Open: | 214.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 214.00p - 214.00p |
| 52wk Range: | 187.50p - 292.00p |
| Market Capitalisation: | £1.84b |
| VWAP: | 204.95252p |
| Shares in Issue: | 859.52m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 235 | 209.80p | Ordinary |
11:19:57 - 11-Mar-26 |
| Buy* | 11 | 210.00p | Ordinary |
11:18:40 - 11-Mar-26 |
| Buy* | 11 | 209.80p | Ordinary |
11:18:39 - 11-Mar-26 |
| Buy* | 1 | 212.00p | SI Trade |
11:09:46 - 11-Mar-26 |
| Buy* | 4 | 213.74p | Ordinary |
11:03:24 - 11-Mar-26 |
| Sell* | 780 | 203.00p | Ordinary |
10:36:07 - 11-Mar-26 |
| Buy* | 1 | 214.00p | SI Trade |
10:00:49 - 11-Mar-26 |
| Buy* | 25 | 213.65p | Ordinary |
08:31:12 - 11-Mar-26 |
| Sell* | 4 | 202.00p | SI Trade |
08:00:28 - 11-Mar-26 |
| Buy* | 2 | 214.00p | Suspected BUY Trade |
08:00:28 - 11-Mar-26 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 9th Mar 2026 9:30 am | RNS | Update on Licensed Oncology Product in China |
| 6th Mar 2026 8:30 am | RNS | Directorate change |
| 5th Mar 2026 1:00 pm | RNS-R | Publication of Form 20-F |
| 5th Mar 2026 11:00 am | RNS | 2025 Full Year Results and Business Updates |
| 4th Mar 2026 8:30 am | RNS-R | HUTCHMED Initiates Global Trial of ATTC Candidate |
| 6th Feb 2026 8:30 am | RNS | HUTCHMED to Announce 2025 Final Results |
| 14th Jan 2026 7:00 am | RNS-R | Publication of Phase III Results in The Lancet |
| 7th Jan 2026 7:00 am | RNS-R | Positive Topline Results of Phase III Trial |
| 5th Jan 2026 7:00 am | RNS-R | Surufatinib + Camrelizumab PDAC Phase 3 initiation |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |